Positive Phase III data for somatrogon in children (3 to <18 years) with growth hormone deficiency

Somatrogon is a long-acting formulation of somatropin. Data from the study showed once-weekly administration improved mean overall Life Interference total score after 12 weeks versus daily somatropin (Genotropin®) (difference of -15.49; 95% CI -19.71, -11.27; p<0.0001).

Biospace Inc.